Issue 37, 2018

A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents

Abstract

Zirconium-89 is currently being used in numerous clinical trials involving monoclonal antibodies and positron emission tomography. This report describes a revised strategy that reduces preparation time while increasing the specific activity of clinically relevant immuno-PET agents. Additionally, it demonstrates that n-acetyl-L-cysteine acts as a superior radioprotective agent that improves long-term stability without compromising antigen affinity in vivo.

Graphical abstract: A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents

Supplementary files

Article information

Article type
Paper
Submitted
07 May 2018
Accepted
12 Aug 2018
First published
04 Sep 2018

Dalton Trans., 2018,47, 13214-13221

A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents

N. B. Bhatt, D. N. Pandya, S. Rideout-Danner, H. D. Gage, F. C. Marini and T. J. Wadas, Dalton Trans., 2018, 47, 13214 DOI: 10.1039/C8DT01841C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements